KGKevin Gruffydd-Jones

Kevin Gruffydd-Jones

*This is an algorithmically generated author record based on publicly available information.

Kevin Gruffydd-Jones has a total of 151 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    BTS/NICE/SIGN guideline for asthma 2024: Diagnosis, monitoring and chronic asthma management. How does this compare to GINA 2024?

    by Kevin Gruffydd-Jones

    The British BTS/NICE/SIGN Asthma Guideline was launched in November 2024 and represents a major shift in asthma diagnosis and management in the United Kingdom. The British Guideline places emphasis on markers of eosinophilic inflammation as initial key diagnostic tests whereas GINA places emphasis on test of reversible airflow limitation. Both documents acknowledge that there is no one “gold-standard” test and, especially in areas of the world where the is limited or delayed access to tests, the IPCRG “jigsaw puzzle” approach to asthma diagnosis may he particularly useful. The BTS/NICE/SIGN guideline provides strong economic evidence to support the GINA strategy approach of single anti-inflammatory-reliever (AIR) and Maintenance and Reliever (MART) therapies as the cornerstone of asthma management in people age 12 and over.


  • Open Access

    Managing chronic cough in adults in primary care

    by Kevin Gruffydd-Jones, Sean Parker

    Recent British Thoracic Society guidance on chronic cough in adults2 outlines a pragmatic and evidence-based approach (Figure 1). After the exclusion of common disease and aggravants, cough may be due to one or several observable ‘treatable traits’ (Figure 2).


  • Managing bronchiectasis in adults in primary care: a clinical update

    by Kevin Gruffydd-Jones, Duncan Keeley, James Wildgoose, Adam Hill

    A diagnosis of bronchiectasis should be suspected when a patient presents with a recurrent or persistent (>8 weeks) cough with production of purulent or mucopurulent sputum.1


  • Open Access

    The Burden of Self-Reported Rhinitis and Associated Risk for Exacerbations with Moderate-Severe Asthma in Primary Care Patients

    by Vicky Kritikos, David Price, Alberto Papi, Antonio Infantino, Björn Ställberg, Dermot Ryan, Federico Lavorini, Henry Chrystyn, John Haughney, Karin Lisspers, et al.

    Purpose: There is a dearth of research regarding the prevalence and nature of patient-reported rhinitis and its relationship with risk of asthma exacerbations. The aim of this study was to (i) determine the prevalence, severity and treatment of self-reported rhinitis symptoms among adults aged ≥ 18 years with asthma treated at Global Initiative for Asthma (GINA) Step 3 and above and (ii) compare the demographics, clinical characteristics, medication use, side-effects and healthcare practitioner review between patients who report rhinitis symptoms and those who do not and (iii) determine whether patient-reported rhinitis is associated with risk of asthma exacerbations in the total patient sample. Patients and Methods: This analysis used data from the iHARP (Initiative Helping Asthma in Real-life Patients) asthma review service – a cross-sectional observational study (2011 and 2014) in seven countries that captured data on patient demographics, rhinitis symptoms, asthma symptoms, indicators of exacerbations, medication use, oropharyngeal effects and side-effects, using practitioner- and patient-reported questionnaires. Comparisons between patients with and without rhinitis were tested. Univariate logistic regression was used to identify variables associated with risk of exacerbations for entry into multivariable logistic regression. Results: This report contains data from 4274 patients: 67.4% (2881/4274) reported rhinitis symptoms and of which 65.7% (1894/2881) had not received a doctor diagnosis; 36.5% (1052/2881) had moderate-severe rhinitis, 12.4% (358/2881) had used intranasal corticosteroids and 19.8% (569/2881) oral antihistamines. Patients with coexisting moderate-severe rhinitis were more likely to have GINA-defined uncontrolled asthma than those with mild rhinitis or no rhinitis. Moderate-severe rhinitis was associated with 40% increased risk of asthma exacerbations (OR=1.40, 95% CI: 1.02– 1.90). Conclusion: This study identified a major gap in the diagnosis and management of rhinitis in a cohort of people with asthma treated at GINA Step 3 and above who are managed in general practice. It highlights the need for practitioners to identify, evaluate and optimally treat rhinitis in adults with asthma, which is a significant factor associated with exacerbation risk.


  • Open Access

    Efficacy and Safety of LAMA/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment Comparisons

    by John R Hurst, Kevin Gruffydd-Jones, Mousumi Biswas, Deniz Guranlioglu, Martin Jenkins, Neda Stjepanovic, Arushi Bamrara

    Background: This literature review assessed comparative efficacy and safety of long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) fixed-dose combinations (FDCs) in patients with COPD and moderate-to-very severe airflow limitation, using evidence from direct (head-to-head) and indirect treatment comparisons. Methods: Two systematic literature reviews were conducted to identify direct comparisons (head-to-head randomized controlled trials [RCTs]) and indirect comparisons (network meta-analyses [NMAs]; indirect treatment comparisons; meta-analyses) in patients with COPD with moderate-to-very severe airflow limitation. Study/Analysis characteristics, eligibility criteria, patient characteristics, and overall conclusions were extracted from relevant publications. The review of indirect comparisons focused on NMAs reporting efficacy outcomes at 12 and 24 weeks of treatment (established durations of symptomatic studies in COPD recommended by regulators). Results: Direct comparisons: Four RCTs that provided head-to-head comparisons of LAMA/LABA FDCs were identified, and these varied in their study design, included patient population and reported endpoints. While some differences in lung function outcomes were noted, where assessed, LAMA/LABA FDCs had comparable efficacy in improving symptoms, health status, exacerbations, and comparable safety profiles. However, the differences in study methodology and patient characteristics between these studies made it difficult to draw generalizable conclusions regarding the comparative effectiveness of LAMA/LABA FDCs from the direct comparisons alone. Indirect comparisons: Six NMAs were identified that reported indirect comparisons between LAMA/LABA FDCs; five of these were within the pre-defined scope of this review. Although the scope of each NMA varied, all five concluded that LAMA/LABA FDCs were generally comparable in terms of lung function improvements, patient-reported outcomes, and safety (where assessed). Conclusion: Although there were some inconsistencies between the outcomes of RCTs and NMAs for lung function, the totality of lung function, symptoms, exacerbations, and safety data suggests that currently available LAMA/LABA FDCs have comparable efficacy and safety in patients with COPD and moderate-to-very severe airflow limitation.


  • Open Access

    Working for Better Asthma Control: How Can We Improve the Dialogue Between Patients and Healthcare Professionals?

    by Kevin Gruffydd-Jones, Kjeld Hansen

    Asthma is a chronic disease affecting more than 300 million people globally. Poor asthma control that leads to unnecessary symptoms is estimated to affect


  • Open Access

    Asthma impacts on workplace productivity in employed patients who are symptomatic despite background therapy: a multinational survey

    by Kevin Gruffydd-Jones, Mike Thomas, Miguel Roman-Rodríguez, Antonio Infantino, J. Mark FitzGerald, Ian Pavord, Jennifer M. Haddon, Ulrich Elsasser, Christian Vogelberg

    Background: Asthma affects millions of people worldwide, with many patients experiencing symptoms that affect their daily lives despite receiving long-term controller medication. Purpose: Work is a large part of most people’s lives, hence this study investigated the impact of uncontrolled asthma on work productivity in adults receiving asthma maintenance therapy. Patients and methods: An online survey was completed by employed adults in Brazil, Canada, Germany, Japan, Spain and the UK. Participants were confirmed as symptomatic using questions from the Royal College of Physicians’ 3 Questions for Asthma tool. The survey contained the Work Productivity and Activity Impairment – Specific Health Problem questionnaire and an open-ended question on the effect of asthma at work. Results: Of the 2,055 patients on long-term maintenance therapy screened, 1,598 were symptomatic and completed the survey. The average percentage of work hours missed in a single week due to asthma symptoms was 9.3%, ranging from 3.5% (UK) to 17.4% (Brazil). Nearly three-quarters of patients reported an impact on their productivity at work caused by asthma. Overall work productivity loss (both time off and productivity whilst at work) due to asthma was 36%, ranging from 21% (UK) to 59% (Brazil). When asked how asthma made participants feel at work, many respondents highlighted how their respiratory symptoms affect them. Tiredness, weakness and mental strain were also identified as particular challenges, with respondents describing concerns about the perception of colleagues and feelings of inferiority. Conclusions: This study emphasizes the extent to which work time is adversely affected by asthma in patients despite the use of long-term maintenance medication, and provides unique personal insights. Strategies to improve patients’ lives may include asthma education, optimizing asthma management plans and running workplace well-being programs. Clinicians, employers and occupational health teams should be more aware of the impact of asthma symptoms on employees, and work together to help overcome these challenges.


  • Open Access

    Primary care implications of the British Thoracic Society Guidelines for bronchiectasis in adults 2019

    by Kevin Gruffydd-Jones, Duncan Keeley, Vikki Knowles, Ximena Recabarren, Alex Woodward, Anita L. Sullivan, Michael R. Loebinger, Karen Payne, Alex Harvey, Lizzie Grillo, et al.

    The British Thoracic Society (BTS) Guidelines for Bronchiectasis in adults were published in January 2019, and comprise recommendations for treatment from primary to tertiary care. Here, we outline the practical implications of these guidelines for primary care practitioners. A diagnosis of bronchiectasis should be considered when a patient presents with a recurrent or persistent (>8 weeks) productive cough. A definitive diagnosis is made by using thin-section chest computed tomography (CT). Once diagnosed, patients should be initially assessed by a specialist respiratory team and a shared management plan formulated with the patient, the specialist and primary care teams. The cornerstone of primary care management is physiotherapy to improve airway sputum clearance and maximise exercise capacity, with prompt treatment of acute exacerbations with antibiotics.


  • Open Access

    Unmet needs in asthma

    by Kevin Gruffydd-Jones

    Despite advances in the diagnosis and management of asthma, uncontrolled disease is still associated with a substantial mortality and morbidity burden. Patients often overestimate their level of asthma control while also reporting that asthma symptoms affect their quality of life and ability to work or study. There is some evidence of success with primary prevention measures in high-risk children and the secondary prevention of asthma in sensitized individuals or those at risk of developing occupational asthma. There are challenges with diagnosis – with under- and overdiagnosis and misdiagnosis being common – and in the treatment of asthma, despite clear treatment guidelines. In particular, severe asthma presents a huge challenge to the clinician, and its complex and heterogeneous nature warrants a personalized medicine approach to match therapies to individual patients. However, the tools for this are currently lacking in primary care. This article reviews the current unmet need in the diagnosis and clinical management of asthma, and provides an overview of the limitations of current therapies.


  • A woman with breathlessness: a practical approach to diagnosis and management

    by Alan Kaplan, Kevin Gruffydd-Jones, Frederik van Gemert, Bruce J Kirenga, Andrew Rl Medford

    The Primary Care Respiratory Journal (PCRJ) is a peer-reviewed, Medline-listed international academic journal relevant to all those working in primary care world-wide, particularly those with an interest in the primary care prevention and management of respiratory and allergic diseases.